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Abstract The Alzheimer's disease flA4 amyloid precursor protein (APP) has been suggested tobe involved in regulation of cell growth, neurite 
outgrowth and adhesiveness through binding to beparin sulfate proteoglycans. In order to unravel the molecular mechanisms underlying those 
functions in vitro we show that APP binds in a time dependent and saturable manner to the glycosaminoglycan side-chains ofproteoglycans but 
not to chondroitinsulfate. Wealso demonstrate aninteraction between the high affinity beparin binding site within the carbohydrate domain of APP 
and the zinc(II) binding site of APP. We show that he affinity for beparin is increased two- to four-fold in the presence ofmicromolar zinc(II). Thus 
micromolar concentrations of zinc(II) appear to be able to modulate the binding of APP to heparin side-chains ofproteoglycans and as shown 
previously [Science 265 (1994) 1464-1467] toinduce the aggregation fsoluble amyloid flA4 protein. 
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1. Introduction 
The amyloid precursor protein (APP) from which the 39-43 
amino acid polypeptide flA4 is derived represents he prototype 
protein of a superfamily of proteins that are generated from 
alternatively spliced transcripts [2]. APP is synthesized as an 
integral membrane glycoprotein which secretory forms are de- 
rived by proteolytic cleavage within the ectodomain [3,4]. APP 
exists in at least eight distinct isoforms. These are termed L- 
APP677, APP695, L-APP696, APP714, L-APP733, APP751, L-APP752 
and APP770 [5-10]. The flA4 protein is the subunit of the ex- 
tracellular amyloid deposits in Alzheimer's disease. 
Regarding the putative function of APP, APP75 t and APP770 
isoforms which contain a region homologous to the Kunitz 
protease inhibitor (KPI) consensus sequence have a role in 
regulation of extracellular p otease activity [11]. The secreted 
or membrane-associated forms of APP have also been shown 
to be involved in cell growth regulation, to regulate neurite 
length and to participate in neuronal cell and cell-matrix adhe- 
sion [12-14]. The ability of APP to stimulate cell adhesion and 
growth does not depend on the presence of the KPI domain and 
may derive from its high affinities for heparin, heparin sulfate 
proteoglycans [15], laminin and collagen type IV [16-20]. A 
growth-promoting activity on A-1 fibroblasts has been mapped 
to residues 328-332 of the APP695 isoform which lacks the KPI 
domain [21]. APP has been shown to bind zinc(II) and cop- 
per(II) at two distinct sites [17,22]. The zinc(II) binding site of 
APP has been shown to reside within residues 181-200 and to 
be encoded by exon 5. A copper(II) binding peptide of APP 
containing the consensus motif for type II copper binding pro- 
teins corresponds toresidues 135-155 which are encoded within 
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exon 4. Zinc(II) and copper(II) binding of APP are suggested 
to control APP conformation and stability [17,22]. 
We have analyzed the specificity of binding to the glycosam- 
inoglycans heparin and chondroitinsulfate, and the effect of 
zinc(II) on heparin binding of APP. Using surface plasmon 
resonance (SPR) we were able to show that zinc(II) binding 
strengthens the binding to heparin thus demonstrating an inter- 
action of residues involved in ligand binding which are located 
in different domains. This suggests that APP is an allosteric 
protein. 
2. Experimental 
2.1. Purification and radioiodination of APP 
APP695 was isolated from rat brain as described previously [17]. 
Radio-iodination ofpurified rat brain APP was done with the Iodo- 
Beads iodination reagent (Pierce). Free iodine was removed by affinity 
chromatography onbeparin Sepharose CL6B (Pharmacia). The spe- 
cific activity of the radioiodinated APP was 5 x 105 to 1 x 106 cpm/ 
pmol. 
2.2. APP-heparin binding 
To determine the dissociation constant of APP-heparin binding, 20 
/zl of beparin-Sepharose wasincubated with increasing concentrations 
( 10 -9 to 10-12 M) of t 22i.APp (200/zl of 150 mM NaC1, 10 mM Tris-HC1, 
pH 7.5, 0.1% BSA). The amount of APP bound was quantified by liquid 
scintillation counting. Values are corrected for non-specific binding to' 
Sepharose CL-6B. 
2.3. Surface plasmon resonance (SPR) 
Surface plasmon resonance analysis of heparin binding (BIAcore, 
Pharmacia; [23]) was done in HBS (10 mM HEPES, pH 7.4, 150 mM 
NaC1, 0.005% BIAcore Surfactant P20) at a flow rate of 5/zl/min 
according to the instructions ofthe manufacturer. For all experiments 
200-300 ng of rat brain APP was used for coupling to the sensor chip 
(thiol coupling method) and gave 5,000-7,000 response units ~arre- 
sponding to 0.06 pmol APP/mm 2of the sensor chip (coupling yield of 
2-3%). Heparin bound to APP on the sensor chip surface was removed 
by injecting 20/zl of 1 M NaC1. Free heparin (Sigma, H-7005) and 
chondroitin sulfate A (Sigma, C-8529) dissolved in 1 x HBS were 
injected without and with 100/zM of the following metal ions: ZnCI2, 
COC12, CaCI2, MgC12. Injections were done with one metal ion at a time. 
Injections were repeated two times independently and increase of 
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response units taken from the dissociation phase averaged. Saturating 
effect of zinc(II) for heparin binding: the increase of heparin binding 
was measured after injecting 2.5 ng of free heparin together with in- 
creasing concentrations of zinc(II). 
In SPR, the observed change in response units is either due to a 
conformational change of the immobilized protein or the binding of a 
ligand provided both are large enough to alter the refractive index at 
the sensor chip surface [17,23]. 
3. Results 
3.1. Heparin binding of rat brain APP 
A solid phase binding assay showed that binding of radi- 
oiodinated APP to heparin is time dependent (Fig. 1A) reaching 
half maximal binding after 8 min at 4°C. This interaction was 
concentration dependent over nanomolar to picomolar APP 
concentrations (Fig. 1B). Scatchard transformation of these 
data revealed the presence of a high affinity binding site of APP 
for heparin with an apparent dissociation constant of 300 pM. 
The measured kinetic parameters are dependent on the working 
method used and may only partially reflect he in vivo situation. 
3.2. Zinc modulation of the heparin binding site in vitro 
Since the stability of APP enriched by heparin affinity 
chromatography from plasma of patients with Alzheimer's dis- 
ease was greatly reduced in the presence of 20/tM zinc(II) and 
since APP alone was found to bind 65Zn2+ [22], we studied the 
influence of zinc(II) on APP heparin binding by surface plas- 
mon resonance (SPR) using biosensor based technology. This 
technique allows to monitor at high sensitivity the binding of 
those ligands to the protein immobilized to the SPR sensor chip 
surface whose binding results in a change of the reflected mon- 
ochromatic light. Briefly, proteins are covalently coupled via a 
dextrane matrix on a gold surface of a sensor chip. The sensor 
chip is mounted in a flow cartridge which allows continous flow 
of buffer and the sensor chip surface forms one wall of the flow 
cell. The refraction of light (760 nm) from the gold layer is 
recorded and compared with the reflection obtained after addi- 
tion of ligands. The difference in response units is a measure 
of the deviation of light upon ligand binding. Such a difference 
is expected to be observed if the surface area of the ligand is 
large enough, or if in the case of a small igand the protein itself 
undergoes a significant conformational change upon ligand 
binding. As shown in Fig. 2, heparin which belongs to the 
former group of large ligands fulfils the criteria to be analyzed 
for its binding to APP by SPR. A difference in refractive index 
is caused by mass changes on the sensor chip surface when the 
analyte heparin binds to immobilized APP. An increase of 70 
response units (RU) and fast association was observed after 
injecting 75ng heparin (Fig. 2A). The interaction of APP and 
heparin could be shown to be specific because other negatively 
charged polymers like chondroitin sulfate A cannot replace 
heparin (Fig. 2B). Zinc(II) binding to APP does not alter the 
refractive index (Fig. 2C) and cannot be directly analyzed by 
SPR. If zinc(II) binding would alter APP conformation i such 
a wa~, that heparin binding is influenced this should then be 
detected by SPR. Indeed, at low concentrations of zinc(II) (50 
nM to 200 nM) the refractive index observed by heparin bind- 
ing of rat brain APP increases (Fig. 3A). Since the zinc(II) 
binding site of APP was shown to have lower affinity to other 
divalent metal ions such as Ca 2+, Co 2+ or Mg 2÷, we compared 
the effect of these ions with that for zinc(II). This comparison 
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Fig. 1. Time course of ~25I-APP binding to heparin Sepharose (A). 
Maximal binding corresponds to 100%. Equilibrium measurement of
'25I-APP to heparin (B). Data represent mean values of two independ- 
ent experiments. Scatchard analysis of APP binding to heparin reveals 
a dissociation constant of 0.3 nM for APP695 (inset). 
showed that the increase of heparin binding to APP is strongest 
for zinc(II), followed by Co 2÷, Ca 2+ and Mg 2+ (Fig. 3B). The 
latter metal ions are half as effective as zinc(II) which is in good 
agreement with their binding constants for the zinc(II) binding 
site of APP [22]. The saturation of the modulating effect of 
zinc(II) on heparin binding of APP is reached at 70/.tM zinc(II) 
(Fig. 3A). This concentration fzinc(II) is within the physiolog- 
ical levels of zinc(II) in brain. We have shown previously [22] 
that direct binding of zinc(II) to heparin does occur below these 
concentrations and therefore cannot account for the effect. 
The zinc(II) concentrations in the brain interstitium fluctuate 
from an average level of 0.15/2M to 300/.tM during synaptic 
transmission [24-26]. Hence, the modulation of APP binding 
to heparin occurs over a range of zinc(II) concentrations that 
would be way below those encountered physiologically. The 
APP binding site for zinc(II) has been previously identified. It 
includes residues 181-200 of APP695 encoded within exon 5 [22]. 
It is located N-terminal to the heparin site that is encoded by 
exons 9 and 10 (G. Multhaup, unpublished). 
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4. Discussion 
Heparin binding to APP occurs very rapidly irrespective of 
the immobilized ligand, either heparin coupled to Sepharose or 
APP immobilized to the SPR sensor chip. Maximal binding was 
reached after approximately 30min at 4°C and after one min- 
ute at 25°C. 
The high salt concentration atwhich APP elutes from hepa- 
rin-Sepharose is greater than physiological (620--1,000 mM 
NaC1; G. Multhaup, unpublished) and is therefore already an 
indication of heparin affinity and useful for comparative pur- 
poses. This approximates to the highest values found in the 
literature i.e. for antithrombin, a heparin-binding serine pro- 
teinase inhibitor that elutes at 750 mM NaC1 [27]. More rigor- 
ous measurements revealed the apparent dissociation constant 
derived from Scatchard transformation as 3 x 10 -1° M for 
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Fig. 2. Binding of heparin to rat brain APP immobilized to the sensor 
chip surface. 75 ng of free heparin (A) and 75 ng of chondoitin sulfate 
A (B) were injected for the time indicated by the arrow. The dissociation 
of heparin from APP (x-axis) and the amount of heparin bound (y-axis) 
are given by the hatching (A). Injection of chondroitin sulfate A and 
HBS containing 100 #M zinc(II) did not result in a significant increase 
of response units above the baseline (B and C). 
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Fig. 3. Modulation of APP heparin binding by Zn 2+ at fixed heparin 
concentration (2.5 ng) (A) and at 100 #M Zn 2+ (filled squares), Ca 2+ 
(diamonds) Co 2+ (triangles) and Mg :+ (circles) at increasing heparin 
concentrations (B) analysed by surface plasmon resonance (SPR). Re- 
sults are expressed as increase of relative response units in heparin 
binding upon addition of metal ions. 
APP-binding to heparin-Sepharose. This is in good agreement 
with Kd values obtained by analysis of the binding of heparin 
to membranes i olated from LX-1 cells [28] but is approxi- 
mately 60 times lower than that for binding of NCAM to 
heparin and even lower than that for homophilic binding of 
NCAM to NCAM [29]. 
APP binding to heparin in vitro suggests that APP growth 
stimulation may be mediated through this heparin-binding site 
in vivo. In addition, a low affinity APP heparin binding site 
located within residues 96-110 was shown to be involved in the 
regulation of neurite outgrowth [30]. This site binds three or- 
ders of magnitude l ss tightly to heparin than the high affinity 
site described here. But both sites appear to be associated with 
growth activity. 
Zinc(II), known to occur in vesicles at concentrations of up 
to 300 #M in zinc(II)-sensitive mossy fibres of the hippocampus 
and to be released uring neuronal activity [31] is shown here 
to strengthen the binding of APP to heparin. Zinc(II) is there- 
fore in principle capable to modulate the interaction of APP 
with the heparan sulfate moiety of proteoglycans (HSPG). In 
brain HSPG's are exposed on the cell surface as receptors and 
are major constituents of the extracellular matrix [32]. 
A functional zinc(II) binding site on APP is of great impor- 
tance because an abnormality of zinc metabolism in AD and 
Downs syndrome has been reported [33,34]. A disturbed home- 
ostasis of extracellular zinc(II) in Alzheimer's disease [22] may 
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therefore interfere with the normal binding of APP to heparin- 
like molecules uch as HSPG's [19] which are known to alter 
protein conformation, and the clearance and processing of 
bound proteins [35]. Zinc(II) binding may also influence APP 
processing since the stability of APP enriched by heparin affin- 
ity chromatography from plasma of patients with AD was 
greatly reduced at low concentrations of zinc [22]. Finally, at 
micromolar concentrations of free zinc(II) soluble flA4 mole- 
cules are precipitated [1]. This recent finding that zinc(II) bind- 
ing to flA4 results in accelerated aggregation of synthetic flA4 
peptides and in insoluble precipitates with the tinctorial proper- 
ties of amyloid plaque deposits in Alzheimer's disease suggests 
that zinc(II) not only regulates the normal APP function but 
may also play a crucial role in amyloid depositions in Alz- 
heimer's disease. 
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